[Acetylsalicylic acid in patients with planned (elective) interventions on the coronary arteries. Risks and benefits].
In a review of the literature describes the risks and benefits of surgical interventions, in particular, coronary artery bypass grafting in patients with coronary artery disease receiving antiplatelet therapy with no cancellation or late withdrawal of acetylsalicylic acid (ASA). The data supporting a moderate - without increasing the frequency of reoperation and blood transfusion - an increased risk of perioperative bleeding in cases where operations are conducted against a background of aspirin therapy. At the same time showed a significant reduction in the risk of perioperative cardiovascular complications and improve survival after intervention, which did not occur before the removal of the drug ASA.